Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.
相关临床试验
3
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1949
进行中（未招募）
2
66.7%
Unknown
1
33.3%
暂无批准数据
- The global 3D printing medical devices market is projected to grow from USD 3.71 billion in 2025 to USD 18.61 billion by 2035, at a CAGR of 17.49%. - Key drivers include rising demand for patient-specific implants and prosthetics, increased use of surgical guides and anatomical models, and advances in biocompatible materials. - Major players such as Stratasys, 3D Systems, and Materialise are launching new multi-material and workflow automation technologies to expand clinical applications. - Technologies including selective laser sintering, bioprinting, and AI-powered design software are enabling better patient outcomes at reduced costs and faster treatment times.
- Elixir Medical's DynamX Bioadaptor demonstrated significantly lower target lesion failure rates (2.8% versus 7.8%, p=0.020) compared to Resolute Onyx drug-eluting stents in the 445-patient BIOADAPTOR randomized controlled trial. - The bioadaptor achieved an 88% reduction in cardiovascular death (0.5% versus 3.7%, p=0.020) with no new events in the bioadaptor arm between three and four years. - Unlike traditional drug-eluting stents that permanently cage arteries, the DynamX bioadaptor unlocks after six months to restore vessel pulsatility and compliance while maintaining arterial support. - Results were particularly pronounced in the left anterior descending artery, showing dramatically lower target lesion failure rates (2.7% versus 10.6%, p=0.021) compared to drug-eluting stents.
- Oramed Pharmaceuticals will transfer its proprietary POD™ oral drug delivery technology to Lifeward in exchange for a 49.9% ownership stake in the medical robotics company. - The transaction includes up to $47 million in strategic investment designed to bring Lifeward to profitability while expanding into biotechnology through the oral insulin platform. - Lifeward's existing FDA-approved ReWalk® and AlterG® products generated $26 million in revenue over the last four quarters, providing a foundation for the combined entity. - The POD™ technology targets the $600+ billion injectable drugs market, with lead candidate ORMD-0801 having potential to become the world's first commercialized oral insulin medicine.
- Elixir Medical's DynamX bioadaptor demonstrated a 48% reduction in target lesion failure compared to current-generation drug-eluting stents in a landmark clinical trial presented at TCT 2025. - The coronary implant showed significant benefits from six months through two years, with particular clinical advantages for high-risk patients with acute coronary syndrome. - The device addresses key limitations of traditional stents by unlocking and allowing arteries to return to natural motion after providing initial structural support. - Results mark a major advance in coronary interventions after two decades of limited progress in improving stenting outcomes for cardiovascular disease patients.
- Three-year results from the SPYRAL HTN-ON MED trial demonstrate that Medtronic's Symplicity renal denervation procedure achieved sustained blood pressure reductions of 18.5 mmHg in office-based measurements compared to sham controls. - The randomized, sham-controlled study of 337 patients showed statistically significant improvements in both 24-hour ambulatory and office-based blood pressure measurements through three years of follow-up. - No renal artery stenosis greater than 70% was observed in the treatment group, supporting the long-term safety profile of the radiofrequency-based renal denervation system. - The procedure offers a durable interventional option for hypertensive patients whose blood pressure remains uncontrolled despite antihypertensive medications and lifestyle modifications.
- Medtronic has initiated the ELEVATE-HFpEF pivotal study to evaluate personalized cardiac pacing rates as a novel treatment for heart failure with preserved ejection fraction (HFpEF), a condition affecting 32 million people worldwide. - The randomized, double-blinded trial will enroll up to 700 participants across multiple regions to test conduction system pacing using personalized rates based on body size and heart function. - This represents a potential breakthrough for HFpEF patients who currently have limited treatment options, as traditional pacemakers are not indicated for this condition that affects approximately 50% of all heart failure patients.
- Medtronic received FDA approval for expanded Redo-TAVR indication of its Evolut transcatheter aortic valve replacement systems, allowing implantation inside any failed previously implanted TAV. - The approval covers Evolut PRO+, FX, and FX+ systems for high-risk surgical patients with failing transcatheter heart valves from any manufacturer. - Medtronic launched the RESTORE study to evaluate Redo-TAVR outcomes in 225 participants over five years, focusing on procedural success rates and long-term clinical outcomes. - The expanded indication provides physicians with more treatment options beyond existing valve-in-valve procedures and benefits future TAVR patients by offering intervention possibilities.
- The neuroregeneration therapy market is projected to grow at a 5.3% CAGR from 2024 to 2034, with North America leading the expansion due to advanced healthcare infrastructure and strong research funding. - Recent breakthroughs include Biogen's promising gene therapy trials for Parkinson's disease and BrainStorm Cell Therapeutics' regulatory approval for stem cell-based ALS treatment. - Artificial intelligence, stem cell research, and gene therapy applications are reshaping the therapeutic landscape, with major pharmaceutical companies forming strategic partnerships to accelerate innovation.
